Summit Therapeutics (SMMT) EBIAT (2016 - 2025)
Historic EBIAT for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to -$231.8 million.
- Summit Therapeutics' EBIAT fell 31204.71% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$921.6 million, marking a year-over-year decrease of 36858.94%. This contributed to the annual value of -$221.3 million for FY2024, which is 6400.96% up from last year.
- As of Q3 2025, Summit Therapeutics' EBIAT stood at -$231.8 million, which was down 31204.71% from -$565.7 million recorded in Q2 2025.
- Summit Therapeutics' EBIAT's 5-year high stood at -$19.2 million during Q4 2022, with a 5-year trough of -$565.7 million in Q2 2025.
- In the last 4 years, Summit Therapeutics' EBIAT had a median value of -$56.3 million in 2024 and averaged -$107.3 million.
- As far as peak fluctuations go, Summit Therapeutics' EBIAT surged by 54.71% in 2023, and later plummeted by 83683.53% in 2025.
- Over the past 4 years, Summit Therapeutics' EBIAT (Quarter) stood at -$19.2 million in 2022, then tumbled by 90.17% to -$36.6 million in 2023, then crashed by 67.37% to -$61.2 million in 2024, then tumbled by 278.73% to -$231.8 million in 2025.
- Its EBIAT was -$231.8 million in Q3 2025, compared to -$565.7 million in Q2 2025 and -$62.9 million in Q1 2025.